Table 33Body of evidence for sublingual immunotherapy affecting asthma symptoms in children and adolescents

StudyAllergenComparatorsNumber of ParticipantsRisk of BiasDirection of Change*DirectnessMagnitude of Effect
Pajno 2000117Dust miteSLIT
Placebo
24LowNight: +

VAS: +
DirectNight: Strong
VAS: Strong
Lue 2006120Dust miteSLIT
Placebo
20Medium+DirectStrong
Niu 2006121Dust miteSLIT
Placebo
110Medium+DirectStrong
Hirsch 1997154Dust miteSLIT
Placebo
30Low+DirectStrong
Bahceciler 2001158Dust miteSLIT
Placebo
15Medium+DirectModerate
Ippoliti 2003171Dust miteSLIT
Placebo
86Medium+DirectStrong
Tari, 1990157Dust miteSLIT
Placebo
58Low+DirectModerate
Pajno 2003160ParietariaSLIT
Placebo
30MediumSx: +

VAS: +
DirectSx: Could not determine
VAS: Could not determine*
Valovirta 2006168
Savolainen 2006175
Tree mixHigh dose
Low dose
Placebo
98MediumHigh dose: +

Low dose: +
DirectHigh dose: Strong
Low dose: Moderate

+ = positive; Night = nighttime symptom score; SLIT = sublingual immunotherapy; Sx = asthma symptom score; VAS = visual analogue scale score

*

Data provided in the article was not enough to calculate the magnitude of effect.

From: Results

Cover of Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review
Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review [Internet].
Comparative Effectiveness Reviews, No. 111.
Lin SY, Erekosima N, Suarez-Cuervo C, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.